Table 1.
Study | Number of Treated Patients | Subtype | Drug | ORR(%) | mPFS (mo) |
---|---|---|---|---|---|
Gilbert et al. [84] | 45 | Salivary gland carcinoma | Paclitaxel | 0 | 4 |
Pfeffer et al. [85] | 10 | Adenoid cystic carcinoma | Imatinib | 0 | 6 |
Hotte et al. [86] | 15 | Adenoid cystic carcinoma | Imatinib | 0 | 2.5 |
Ghosal et al. [87] | 28 | Adenoid cystic carcinoma | Imatinib + Cisplatin | 0 | 15 |
Wong et al. [88] | 40 | Adenoid cystic carcinoma | Desatinib | 2.5 | 4.8 |
Chau et al. [89] | 13 | Adenoid cystic carcinoma | Sunitinib | 0 | 7.2 |
Jakob et al. [90] | 19 | Adenoid cystic carcinoma | Gefitinib | 0 | 4.3 |
Locati et al. [91] | 30 | Adenoid cystic + non adenoid cystic carcinoma | Cetuximab | 0 | 6 |
Agulnik et al. [92] | 19 | Adenoid cystic carcinoma | Lapatinib | 0 | 3.5 |
Dillon et al. [93] | 34 | Adenoid cystic carcinoma | Dovitinib | 0 | 8.2 |
Locati et al. [94] | 26 | Adenoid cystic carcinoma | Lenvatinib | 0 | 9.1 |
Tchekmedyian et al. [95] | 32 | Adenoid cystic carcinoma | Lenvatinib | 0 | 17.5 |
Pfister et al. [96] | 32 | Adenoid cystic carcinoma | Lenvatinib | 15.6 | 17.5 |
Ho et al. [97] | 33 | Adenoid cystic carcinoma | Axitinib | 0 | 5.7 |
Ho et al. [98] | 38 | Adenoid cystic carcinoma | Regorafenib | NR | NR |
Thomson et al. [99] | 23 | Adenoid cystic carcinoma | Sorafenib | 0 | 11.3 |
Guigay et al. [100] | 46 | Adenoid cystic carcinoma | Pazopanib | 0 | 5.9 |
Even et al. [101] | 22 | Adenoid cystic carcinoma | NOTCH inhibitor crenigacestat (LY3039478) | NR | 5.3 |
Ferrarotto et.al. [102] | 48 | Solid tumors (adenoid cystic carcinoma) | Brontictuzumab | NR | 2 |
Miranda et al. [103] | 41 | Solid tumors and hematological malignancies (adenoid cystic carcinoma) | CB-103 | NR | 5 |
ACCURACY [104] | 87 | Adenoid cystic carcinoma | AL 101 | 15 | NR |
Dong-Wan et al. [105] | 34 | Adenoid cystic carcinoma | Everolimus | NR | 11.2 |
Fayette et al. NISCAHN. [106] | 46 | Salivary gland carcinoma | Nivolumab | 0 | 4.9 |
KEYNOTE-028 [107] | 26 | Salivary gland carcinoma | Pembrolizumab | 12 | 4 |
Mahmood et al. [108] | 10 | Adenoid cystic carcinoma | Pembrolizumab | 0 | 4.5 |